Practice variation in the re-initiation of dofetilide

An observational study

Mohit K. Turagam, Muhammad R. Afzal, Madhu Reddy, Jayasree Pillarisetti, Madhav Lavu, Donita Atkins, Courtney Jeffrey, Katie Christensen, Rhea Pimentel, Raghuveer Dendi, James Vacek, Jodi Hurwitz, Luigi Di Biase, Andrea Natale, Dhanunjaya Lakkireddy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Dofetilide is a class III antiarrhythmic drug that has been reported to be safe and efficacious in the treatment of atrial dysrhythmias with a known initial risk of QT prolongation and torsades de pointes (TdP). As a result, the Federal Drug Administration (FDA) mandated in-hospital dofetilide initiation and adherence to a common dosing protocol. However, there is a lack of clarity on how to manage dofetilide re-initiation. Methods An observational survey was performed including 347 cardiologists in the United States and worldwide to evaluate the deviations from approved manufacturer's protocol during dofetilide initiation and re-initiation among practicing cardiologists. Results Most practicing cardiologists were cautious about outpatient dofetilide use and adhered to the manufacturer's in-patient dofetilide protocol during de-novo initiation and reported low incidence of TdP in clinical practice. There were substantial differences among practicing cardiologists with deviation from the manufacturer's protocol during re-initiation of dofetilide. About 21% cardiologists always admitted patients to the hospital while 37% admitted patients < 10% of the time for dofetilide re-initiation. Only 4% reported major adverse events with outpatient dofetilide re-initiation. There was also wide variation regarding monitoring of electrolytes and QT interval as an outpatient with dofetilide. Conclusion There is significant practice pattern variation in the use of dofetilide for the management of AF. This degree of variation noted is concerning and is a reflection of the current lack of substantial clinical evidence in the re-initiation dofetilide protocol to help direct the provider.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalInternational Journal of Cardiology
Volume236
DOIs
StatePublished - Jun 1 2017

Fingerprint

Observational Studies
Torsades de Pointes
Outpatients
dofetilide
Anti-Arrhythmia Agents
Electrolytes
Cardiologists
Incidence

Keywords

  • Antiarrhythmic drug
  • Atrial fibrillation
  • Dofetilide
  • Practice pattern
  • Survey
  • Tikosyn

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Turagam, M. K., Afzal, M. R., Reddy, M., Pillarisetti, J., Lavu, M., Atkins, D., ... Lakkireddy, D. (2017). Practice variation in the re-initiation of dofetilide: An observational study. International Journal of Cardiology, 236, 221-225. https://doi.org/10.1016/j.ijcard.2017.01.157

Practice variation in the re-initiation of dofetilide : An observational study. / Turagam, Mohit K.; Afzal, Muhammad R.; Reddy, Madhu; Pillarisetti, Jayasree; Lavu, Madhav; Atkins, Donita; Jeffrey, Courtney; Christensen, Katie; Pimentel, Rhea; Dendi, Raghuveer; Vacek, James; Hurwitz, Jodi; Di Biase, Luigi; Natale, Andrea; Lakkireddy, Dhanunjaya.

In: International Journal of Cardiology, Vol. 236, 01.06.2017, p. 221-225.

Research output: Contribution to journalArticle

Turagam, MK, Afzal, MR, Reddy, M, Pillarisetti, J, Lavu, M, Atkins, D, Jeffrey, C, Christensen, K, Pimentel, R, Dendi, R, Vacek, J, Hurwitz, J, Di Biase, L, Natale, A & Lakkireddy, D 2017, 'Practice variation in the re-initiation of dofetilide: An observational study', International Journal of Cardiology, vol. 236, pp. 221-225. https://doi.org/10.1016/j.ijcard.2017.01.157
Turagam, Mohit K. ; Afzal, Muhammad R. ; Reddy, Madhu ; Pillarisetti, Jayasree ; Lavu, Madhav ; Atkins, Donita ; Jeffrey, Courtney ; Christensen, Katie ; Pimentel, Rhea ; Dendi, Raghuveer ; Vacek, James ; Hurwitz, Jodi ; Di Biase, Luigi ; Natale, Andrea ; Lakkireddy, Dhanunjaya. / Practice variation in the re-initiation of dofetilide : An observational study. In: International Journal of Cardiology. 2017 ; Vol. 236. pp. 221-225.
@article{fb5135e221944ae6905b946898970e85,
title = "Practice variation in the re-initiation of dofetilide: An observational study",
abstract = "Background Dofetilide is a class III antiarrhythmic drug that has been reported to be safe and efficacious in the treatment of atrial dysrhythmias with a known initial risk of QT prolongation and torsades de pointes (TdP). As a result, the Federal Drug Administration (FDA) mandated in-hospital dofetilide initiation and adherence to a common dosing protocol. However, there is a lack of clarity on how to manage dofetilide re-initiation. Methods An observational survey was performed including 347 cardiologists in the United States and worldwide to evaluate the deviations from approved manufacturer's protocol during dofetilide initiation and re-initiation among practicing cardiologists. Results Most practicing cardiologists were cautious about outpatient dofetilide use and adhered to the manufacturer's in-patient dofetilide protocol during de-novo initiation and reported low incidence of TdP in clinical practice. There were substantial differences among practicing cardiologists with deviation from the manufacturer's protocol during re-initiation of dofetilide. About 21{\%} cardiologists always admitted patients to the hospital while 37{\%} admitted patients < 10{\%} of the time for dofetilide re-initiation. Only 4{\%} reported major adverse events with outpatient dofetilide re-initiation. There was also wide variation regarding monitoring of electrolytes and QT interval as an outpatient with dofetilide. Conclusion There is significant practice pattern variation in the use of dofetilide for the management of AF. This degree of variation noted is concerning and is a reflection of the current lack of substantial clinical evidence in the re-initiation dofetilide protocol to help direct the provider.",
keywords = "Antiarrhythmic drug, Atrial fibrillation, Dofetilide, Practice pattern, Survey, Tikosyn",
author = "Turagam, {Mohit K.} and Afzal, {Muhammad R.} and Madhu Reddy and Jayasree Pillarisetti and Madhav Lavu and Donita Atkins and Courtney Jeffrey and Katie Christensen and Rhea Pimentel and Raghuveer Dendi and James Vacek and Jodi Hurwitz and {Di Biase}, Luigi and Andrea Natale and Dhanunjaya Lakkireddy",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.ijcard.2017.01.157",
language = "English (US)",
volume = "236",
pages = "221--225",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Practice variation in the re-initiation of dofetilide

T2 - An observational study

AU - Turagam, Mohit K.

AU - Afzal, Muhammad R.

AU - Reddy, Madhu

AU - Pillarisetti, Jayasree

AU - Lavu, Madhav

AU - Atkins, Donita

AU - Jeffrey, Courtney

AU - Christensen, Katie

AU - Pimentel, Rhea

AU - Dendi, Raghuveer

AU - Vacek, James

AU - Hurwitz, Jodi

AU - Di Biase, Luigi

AU - Natale, Andrea

AU - Lakkireddy, Dhanunjaya

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Dofetilide is a class III antiarrhythmic drug that has been reported to be safe and efficacious in the treatment of atrial dysrhythmias with a known initial risk of QT prolongation and torsades de pointes (TdP). As a result, the Federal Drug Administration (FDA) mandated in-hospital dofetilide initiation and adherence to a common dosing protocol. However, there is a lack of clarity on how to manage dofetilide re-initiation. Methods An observational survey was performed including 347 cardiologists in the United States and worldwide to evaluate the deviations from approved manufacturer's protocol during dofetilide initiation and re-initiation among practicing cardiologists. Results Most practicing cardiologists were cautious about outpatient dofetilide use and adhered to the manufacturer's in-patient dofetilide protocol during de-novo initiation and reported low incidence of TdP in clinical practice. There were substantial differences among practicing cardiologists with deviation from the manufacturer's protocol during re-initiation of dofetilide. About 21% cardiologists always admitted patients to the hospital while 37% admitted patients < 10% of the time for dofetilide re-initiation. Only 4% reported major adverse events with outpatient dofetilide re-initiation. There was also wide variation regarding monitoring of electrolytes and QT interval as an outpatient with dofetilide. Conclusion There is significant practice pattern variation in the use of dofetilide for the management of AF. This degree of variation noted is concerning and is a reflection of the current lack of substantial clinical evidence in the re-initiation dofetilide protocol to help direct the provider.

AB - Background Dofetilide is a class III antiarrhythmic drug that has been reported to be safe and efficacious in the treatment of atrial dysrhythmias with a known initial risk of QT prolongation and torsades de pointes (TdP). As a result, the Federal Drug Administration (FDA) mandated in-hospital dofetilide initiation and adherence to a common dosing protocol. However, there is a lack of clarity on how to manage dofetilide re-initiation. Methods An observational survey was performed including 347 cardiologists in the United States and worldwide to evaluate the deviations from approved manufacturer's protocol during dofetilide initiation and re-initiation among practicing cardiologists. Results Most practicing cardiologists were cautious about outpatient dofetilide use and adhered to the manufacturer's in-patient dofetilide protocol during de-novo initiation and reported low incidence of TdP in clinical practice. There were substantial differences among practicing cardiologists with deviation from the manufacturer's protocol during re-initiation of dofetilide. About 21% cardiologists always admitted patients to the hospital while 37% admitted patients < 10% of the time for dofetilide re-initiation. Only 4% reported major adverse events with outpatient dofetilide re-initiation. There was also wide variation regarding monitoring of electrolytes and QT interval as an outpatient with dofetilide. Conclusion There is significant practice pattern variation in the use of dofetilide for the management of AF. This degree of variation noted is concerning and is a reflection of the current lack of substantial clinical evidence in the re-initiation dofetilide protocol to help direct the provider.

KW - Antiarrhythmic drug

KW - Atrial fibrillation

KW - Dofetilide

KW - Practice pattern

KW - Survey

KW - Tikosyn

UR - http://www.scopus.com/inward/record.url?scp=85013173822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013173822&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.01.157

DO - 10.1016/j.ijcard.2017.01.157

M3 - Article

VL - 236

SP - 221

EP - 225

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -